Search research articles
Contact Us
Filters
Showing results (71-80 of 85) with videos related to
Page
of 9
Sort By:
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
June 20, 2026
Patient Perspectives on Reirradiation for Recurrent Cancer, to Inform Future Clinical Trial Design
F Slevin, S Kendal, A L Appelt, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
September 26, 2020
Predicting the Risk of Disease Recurrence and Death Following Curative-intent Radiotherapy for Non-small Cell Lung Cancer: The Development and Validation of Two Scoring Systems From a Large Multicentre UK Cohort
M Evison, E Barrett, A Cheng, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
July 1, 2020
Palliative Lung Radiotherapy: Higher Dose Leads to Improved Survival?
T S Lewis, J A Kennedy, G J Price, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
April 17, 2021
Neutrophil-Lymphocyte Ratio and Absolute Lymphocyte Count as Prognostic Markers in Patients Treated with Curative-intent Radiotherapy for Non-small Cell Lung Cancer
A Punjabi, E Barrett, A Cheng, et al.
ESMO Open
|
May 28, 2025
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trial
M C Garassino, J Khalifa, M Reck, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 1, 2025
Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group
E Xenophontos, N Giaj Levra, V Durieux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 27, 2020
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
L Paz-Ares, A Spira, D Raben, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 30, 2026
Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?
A Mavrikios, M Bortolot, C Le Péchoux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)
S Peters, U Dafni, M Boyer, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
November 12, 2021
Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK
K Banfill, W Croxford, I Fornacon-Wood, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 85) with videos related to
Sort By:
Page
of 9
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
June 20, 2026
Patient Perspectives on Reirradiation for Recurrent Cancer, to Inform Future Clinical Trial Design
F Slevin, S Kendal, A L Appelt, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
September 26, 2020
Predicting the Risk of Disease Recurrence and Death Following Curative-intent Radiotherapy for Non-small Cell Lung Cancer: The Development and Validation of Two Scoring Systems From a Large Multicentre UK Cohort
M Evison, E Barrett, A Cheng, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
July 1, 2020
Palliative Lung Radiotherapy: Higher Dose Leads to Improved Survival?
T S Lewis, J A Kennedy, G J Price, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
April 17, 2021
Neutrophil-Lymphocyte Ratio and Absolute Lymphocyte Count as Prognostic Markers in Patients Treated with Curative-intent Radiotherapy for Non-small Cell Lung Cancer
A Punjabi, E Barrett, A Cheng, et al.
ESMO Open
|
May 28, 2025
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trial
M C Garassino, J Khalifa, M Reck, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 1, 2025
Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group
E Xenophontos, N Giaj Levra, V Durieux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 27, 2020
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
L Paz-Ares, A Spira, D Raben, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 30, 2026
Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?
A Mavrikios, M Bortolot, C Le Péchoux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)
S Peters, U Dafni, M Boyer, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
November 12, 2021
Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK
K Banfill, W Croxford, I Fornacon-Wood, et al.
Page
of 9